Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103610 · ClinicalTrials.gov registry record · Phase 3
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
NCT00103610 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 298 participants.
The verdict
NCT00103610, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in non-Hodgkin's lymphoma patients for autologous transplantation.
Interventions
- DRUG Granulocyte colony-stimulating factor plus plerixafor
- DRUG Granulocyte colony-stimulating factor plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103610
The ClinicalTrials.gov registry entry for NCT00103610 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Granulocyte colony-stimulating factor plus plerixafor is the first listed.
NCT00103610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103610 about?
NCT00103610 is a clinical study titled "Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients". The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in non-Hodgkin's lymphoma patients for autologous...
What is the current status of trial NCT00103610?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2005-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00103610?
The interventions under investigation include: Granulocyte colony-stimulating factor plus plerixafor (DRUG), Granulocyte colony-stimulating factor plus placebo (DRUG).
Who is sponsoring clinical trial NCT00103610?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.